INTRODUCTION AND OBJECTIVES: Traditionally, renal angiomyolipoma (AML) >4cm were treated with (angioembolisation, radiofrequency ablation, surgery) due to the risk of hemorrhage. The aim of the study was to delineate the natural history of AMLs including growth rates and need for intervention.
INTRODUCTION AND OBJECTIVES: Traditionally, renal angiomyolipoma (AML) >4cm were treated with (angioembolisation, radiofrequency ablation, surgery) due to the risk of hemorrhage. The aim of the study was to delineate the natural history of AMLs including growth rates and need for intervention.
METHODS: A retrospective review and update was performed of a previously reported AML series from a radiology database that identified all renal AML lesions between 2002 and 2013 at the Princess Margaret Cancer Center which have now been followed until 2018. We defined lesion size by maximum axial diameter and lesion size at baseline was categorized as 4 or >4 cm. The primary end point was the growth rate of untreated AMLs. We used a linear mixed-effects model to evaluate the association among growth rate, size, and patient factors as well as interventions.
RESULTS: A total of 458 patients with 593 AMLs were identified during the study period with a median follow up of 64.8 months. 90% of the lesions were <4cm at diagnosis. 33 (5.6%) AMLs required 35 interventions-27 embolizations, 2 RFA, 5 had surgery and 1 was treated with mTOR inhibitors. The indications for intervention included 25 for growth, 5 due to a bleed, 3 for patient anxiety and 2 for pain. The median size at intervention was 5.1cm. The average number of scans per lesion (prior to treatment) was 4.5 (range of 1 to 23). For lesions with >1 scan, the median frequency of scans was 0.87 per year. Most (94%) of lesions grew slowly (growth rate of 0.25 cm per year) during the period of observation. The linear mixed-effects model showed that the growth rate (slope) of log-transformed maximal axial diameter was not significantly different between lesions 4 cm (0.02 log cm per year) and those > 4 cm (0.01 log cm per year) (p [ 0.23).
CONCLUSIONS: This large single institution updated series on renal AMLs demonstrates early intervention is not required regardless of the traditional 4cm cut off. The vast majority of AMLs are indolent lesions that are predominantly asymptomatic. Follow up should be no more frequent than annually. Tcsestamibi can aid in the differentiation of benign renal oncocytomas and hybrid oncocytic/chromophobe tumors (HOCTs) from other renal tumor histologies. This observation has since been independently validated by investigators outside of our institution. As a result, we have adopted 99m Tc-sestamibi SPECT/CT in the routine clinical evaluation of patients presenting with an indeterminate renal mass. The objective of this study was to determine the diagnostic performance of this imaging test using available data from published prospective studies as well as results from our clinical practice.
METHODS: Meta-analyses of sensitivity and specificity for 99m
Tcsestamibi SPECT/CT were performed using data from 3 published clinical trials and unpublished clinical data from our institution. Analyses were performed using random effects modeling and Freeman-Tukey double arcsine transformation to stabilize variances. Heterogeneity was assessed by computing the I 2 statistic. Analyses were performed using MedCalc Version 17.9.7 (MedCalc Software bvba, Ostend, Belgium). Only cases with pathologic confirmation of tumor histology were included in the analyses. True positive was defined as any tumor diagnosed as an oncocytoma or HOCT following surgical resection or as an oncocytic renal neoplasms consistent with an oncocytoma on biopsy.
RESULTS: Data from 167 patients with solid renal tumors imaged with 99m Tc-sestamibi SPECT/CT were included in the analysis. Of these, 80 (47.9%) were imaged as part of clinical care at our institution. In total, 60 (35.9%) true positive tumors were imaged. Among the 107 imaged true negative tumors, 64 (59.9%) were clear cell RCC, 14 (13.1%) were papillary RCC, 11 (10.3%) were chromophobe RCC, and 4 (3.7%) were angiomyolipomas. The calculated values of sensitivity and specificity were 86.6% (95% CI 77.3-93.8%, I
2 [ 0%) and 89.1% (95% CI 82.6-94.2%, I
2 [ 0%), respectively. CONCLUSIONS: Combined data from 3 prospective studies and own clinical experience demonstrate that 99m Tc-sestamibi SPECT/ CT accurately differentiates benign renal oncocytomas and HOCTs from other tumor histologies.
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MP14-03 THE UCLA HISTO-GENETIC RISK CLASSIFICATION (U-HGRC) TO
INTRODUCTION AND OBJECTIVES: Thirty percent of patients with localized clear-cell renal cell carcinoma (ccRCC) will ultimately develop recurrence (local or metastatic) after nephrectomy. Current risk stratification systems still misclassify patients. We developed a novel classification integrating cytogenetic findings to better stratify the risk of recurrence and overall survival (OS) after surgery for localized ccRCC.
METHODS: A total of 646 patients from UCLA with ccRCC and tumor cytogenetic analysis, were included in this study. After a logistic regression analysis to select histologic parameters and a principal component analysis for cytogenetic parameters, a CHAID decision tree and Kaplan Meier analysis were used to build the UCLA Histo-Genetic Risk Classification (U-HGRC). Survival analyses of the model were validated on two random samples of 323 patients. Recurrence was defined as any local recurrence or development of new metastasis after surgery.
RESULTS: The T-stage, tumor size, presence of sarcomatoid features, gain of chromosome 5q, loss 10q, and loss X/Y were used to stratify the risk of recurrence of ccRCC into three U-HGRC groups of low (1), intermediate (2) or high-risk (3). After a mean follow-up of 55 months, risk of recurrence (HR[2.44, p[.001 for U-HGRC 2; HR[9.90, p<.0001 for U-HGRC 3), disease-free survival (DFS) (Log-rank p<.0001), risk of death (HR[1.72, p[.033 for U-HGRC 2; HR[4.74, p<.0001 for U-HGRC 3) and OS (Log-rank p<.0001) were significantly different between groups. These findings were validated on two random samples. For the high-risk group, median DFS and OS were 2.7 and 6.3 years, respectively. The 5-year risks of recurrence for U-HGRC group 1, 2 and 3 were 9%, 25% and 62%, respectively. The AUC of
